PARIS, Nov 18 (Reuters) – Sanofi is drawing up a
shortlist of candidates for the post of chief executive to
replace Chris Viehbacher, ousted by the board last month, a
source close to the French drugmaker told Reuters.
Sanofi’s board met earlier on Tuesday and chose director
Jean-Rene Fourtou to lead the appointments and governance
committee that will be tasked with reviewing the shortlist and
selecting the new CEO, said the source.
PARIS, Nov 17 (Reuters) – Sanofi will hold a board
meeting by telephone on Tuesday from 1100 GMT to 1200 GMT, two
sources close to the French drugmaker told Reuters.
The board is set to discuss Sanofi’s situation and
governance after it summarily ousted its chief executive Chris
Viehbacher last month. Chairman Serge Weinberg has taken the
helm while the company looks for a new CEO.
PARIS/LONDON, Nov 2 (Reuters) – Chris Viehbacher speaks
plainly. “We had somewhat of a mess in Brazil,” he told
financial analysts in August 2013, “so that’s why I decided to
Fifteen months later he has gone the same way as the
Brazilian employees he sacked so decisively – fired as chief
executive of French drugmaker Sanofi at a dawn board
meeting, with the “mess in Brazil” cited as one of the reasons.
PARIS (Reuters) – A boardroom tussle brewing for months at Sanofi came to a head on Wednesday when France’s top drugmaker fired its chief executive, wiping more billions off its share price.
While the showdown played out in leaks to national newspapers has stunned investors as a “how not to do it” guide to corporate governance, the writing was on the wall in the deteriorating relationship between Chairman Serge Weinberg and CEO Chris Viehbacher.
PARIS (Reuters) – Sanofi’s board ousted its chief executive of six years at a special meeting on Wednesday, two days after it emerged he had fallen out with the French drugmaker’s chairman, wiping more billions off its market value.
The management turmoil comes at a particularly awkward time for France’s second-biggest listed company, after it warned on Tuesday that growth in its key diabetes business would likely stall next year.
PARIS (Reuters) – Sanofi’s (SASY.PA: Quote, Profile, Research) board ousted its chief executive of six years at a special meeting on Wednesday, two days after it emerged he had fallen out with the French drugmaker’s chairman, wiping more billions off its market value.
The board said Sanofi would continue the strategy of international expansion it had pursued under Chris Viehbacher, blaming his dismissal on poor relations between the CEO and the board.
PARIS (Reuters) – Sanofi’s (SASY.PA: Quote, Profile, Research) board was on the verge of ousting its CEO at a special board meeting on Wednesday, according to Le Monde newspaper, two days after it emerged he had fallen out with the French drugmaker’s chairman.
Board directors were asked late on Tuesday to attend the meeting scheduled at 0700 GMT on Wednesday, a source close to Sanofi told Reuters earlier.
PARIS, Oct 29 (Reuters) – Sanofi will hold a
special board meeting on Wednesday at 0700 GMT to examine the
French drugmaker’s management structure, a source close to
Sanofi told Reuters amid uncertainty over the future of its
The board directors were hastily convened to the meeting on
Tuesday evening, the source said.
PARIS (Reuters) – French biotech firm DBV Technologies – developer of what it says is a breakthrough treatment for peanut allergy sufferers – makes its U.S. market debut on Wednesday, with a Nasdaq listing set to raise funds for further research.
The Paris-listed company, which develops immunotherapy patches for patients with potentially fatal food allergies, is issuing 2.67 million new shares worldwide via a U.S. listing and a private placement which together will raise at least 90 million euros ($114 million).
PARIS (Reuters) – French pharmaceutical firm Nicox (NCOX.PA: Quote, Profile, Research, Stock Buzz) may list its shares on the Nasdaq to attract U.S. investors and gain recognition as an eye drug specialist, its chief executive told Reuters.
Nicox has been refocusing its business around ophthalmology drugs – a market worth $20 billion worldwide – since a bruising setback in 2010, when the U.S. Food and Drug Administration rejected its non-steroidal anti-inflammatory drug naproxcinod, recommending further trials to prove its safety.